These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 21699377)
1. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. Mocikova H; Pytlik R; Markova J; Steinerova K; Kral Z; Belada D; Trnkova M; Trneny M; Koza V; Mayer J; Zak P; Kozak T Leuk Lymphoma; 2011 Sep; 52(9):1668-74. PubMed ID: 21699377 [TBL] [Abstract][Full Text] [Related]
2. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome. Noring K; Carlsten M; Sonnevi K; Wahlin BE BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353 [TBL] [Abstract][Full Text] [Related]
3. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Gentzler RD; Evens AM; Rademaker AW; Weitner BB; Mittal BB; Dillehay GL; Petrich AM; Altman JK; Frankfurt O; Variakojis D; Singhal S; Mehta J; Williams S; Kaminer L; Gordon LI; Winter JN Br J Haematol; 2014 Jun; 165(6):793-800. PubMed ID: 24628515 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Smeltzer JP; Cashen AF; Zhang Q; Homb A; Dehdashti F; Abboud CN; Dipersio JF; Stockerl-Goldstein KE; Uy GL; Vij R; Westervelt P; Bartlett NL; Fehniger TA Biol Blood Marrow Transplant; 2011 Nov; 17(11):1646-52. PubMed ID: 21601641 [TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893 [TBL] [Abstract][Full Text] [Related]
6. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation. Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134 [TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant. Qiao W; Zhao J; Xing Y; Wang C; Wang T Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323 [TBL] [Abstract][Full Text] [Related]
9. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168 [TBL] [Abstract][Full Text] [Related]
10. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT. Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108 [TBL] [Abstract][Full Text] [Related]
11. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244 [TBL] [Abstract][Full Text] [Related]
12. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904 [TBL] [Abstract][Full Text] [Related]
13. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Sucak GT; Özkurt ZN; Suyani E; Yaşar DG; Akdemir ÖÜ; Aki Z; Yeğin ZA; Yağci M; Kapucu ÖL Ann Hematol; 2011 Nov; 90(11):1329-36. PubMed ID: 21437590 [TBL] [Abstract][Full Text] [Related]
20. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. Akhtar S; Rauf SM; Elhassan TA; Maghfoor I Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]